{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:26Z","timestamp":1791908186607,"version":"4.3.4"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012408","name":"Casen Recordati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires some months to be fully evaluated. Considering this, acromegaly treatment should benefit from personalized medicine therapeutic approach by using biomarkers identifying drug response. Pasireotide has been positioned mostly as a compound to be used in\u00a0first-generation SRLs resistant patients and after surgical failure, but sufficient data are now available to indicate it is a first line therapy for patients\u00a0with certain characteristics. Pasireotide has been proved to be useful in patients in which hyperintensity T2 MRI signal is shown and in those depicting low\n                    <jats:italic>SST2<\/jats:italic>\n                    and high expression of\n                    <jats:italic>SST5<\/jats:italic>\n                    , low or mutated\n                    <jats:italic>AIP<\/jats:italic>\n                    condition and sparsely granulated immunohistochemical pattern. This combination of clinical and pathological characteristics is\u00a0unique for certain patients and seems to cluster in the same cases, strongly suggesting an etiopathogenic link. Thus, in this paper we propose to include this clinico-pathologic phenotype in the therapeutic algorithm, which would allow us to use as first line medical treatment those compounds with the highest potential for achieving the fastest control of GH hypersecretion as well as a positive effect upon tumor shrinkage, therefore accelerating the implementation of precision medicine for acromegaly. Moreover, we suggest the development, validation and clinical use of a pasireotide acute test, able to identify patients responsive to pasireotide LAR as the acute octreotide test is able to do for SRLs.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2021.648411","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T08:35:38Z","timestamp":1615883738000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Pasireotide in the Personalized Treatment of Acromegaly"],"prefix":"10.3389","volume":"12","author":[{"given":"Manel","family":"Puig-Domingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Bernab\u00e9u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pic\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Alvarez-Escol\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Jord\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Marques-Pamies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Soldevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Angeles","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Aller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: Acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9465-0","article-title":"Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors","volume":"19","author":"Pedraza-Ar\u00e9valo","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for Acromegaly Management: An Update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Endocrine Society. Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S4.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cen.12797","article-title":"A paradigm shift in the medical treatment of acromegaly: from a \u201ctrial and error\u201d to a personalized therapeutic decision-making process","volume":"83","author":"Gadelha","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0496","article-title":"Pituitary acromegaly: not one disease","volume":"24","author":"Asa","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1065339","article-title":"Puig-Domingo M. A Short Acute Octreotide Test for Response Prediction of Long-term Treatment with Somatostatin Analogues in Acromegalic Patients","volume":"40","author":"Halperin","year":"2008","journal-title":"Horm Metab Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0175","article-title":"The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly","volume":"63","author":"Wang","year":"2016","journal-title":"Endocr J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"Giustina A. A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-38-2-200","article-title":"Inhibitory Effect of Dopaminergic Stimulation on GH Release in Acromegaly","volume":"38","author":"Chiodini","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","article-title":"[Effect of L dopa, dopamine and CB 154 on prolactin secretion from human pituitary adenomas in vitro (proceedings) (author\u2019s transl)]","volume":"39","author":"Peillon","year":"1978","journal-title":"Ann Endocrinol (Paris)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-55-3-589","article-title":"Evidence of Dopamine Receptors in Human Growth Hormone (GH)-Secreting Adenomas with Concomitant Study of Dopamine Inhibition of GH Secretion in a Perifusion System*","volume":"55","author":"Bression","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2443","article-title":"Place of Cabergoline in Acromegaly: A Meta-Analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary"},{"key":"B26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201\u2013995: A very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(88)81192-6","article-title":"In vitro and in vivo inhibition of human small cell lung carcinoma (NCl-H69) growth by a somatostatin analogue","volume":"153","author":"Taylor","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0169-z","article-title":"and Autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2466","article-title":"Barkan A. A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly","volume":"90","author":"Melmed","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0677-y","article-title":"The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3072","article-title":"A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy","volume":"98","author":"Annamalai","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0768-4","article-title":"Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance","volume":"20","author":"Paragliola","year":"2017","journal-title":"Pituitary"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to Somatostatin Analogs in Acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01950","article-title":"Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy","volume":"153","author":"Jaquet","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Cozzi R. Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0832-8","article-title":"Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly","volume":"20","author":"Fahlbusch","year":"2017","journal-title":"Pituitary"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14339","article-title":"Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH producing adenomas","author":"Gil","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0853-x","article-title":"Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly","volume":"52","author":"Losa","year":"2016","journal-title":"Endocrine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5061","article-title":"Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice","volume":"87","author":"Chen","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.148s021","article-title":"Discovery and mechanism of action of pegvisomant","author":"Kopchick","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of Acromegaly with the Growth Hormone\u2013Receptor Antagonist Pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2265.2008.03469.x","article-title":"Long-term experience of pegvisomant therapy as a treatment for acromegaly","volume":"71","author":"Higham","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0673-2","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort","volume":"18","author":"Sievers","year":"2015","journal-title":"Pituitary"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"Neggers","year":"2011","journal-title":"Growth Horm IGF Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01979","article-title":"How to Position Pasireotide LAR Treatment in Acromegaly","volume":"104","author":"Coopmans","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocr Disord"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0478","article-title":"GHRH excess and blockade in X-LAG syndrome","volume":"23","author":"Daly","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0413-y","article-title":"Pasireotide in Acromegaly: A Review","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0332","article-title":"Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study","volume":"8","author":"Lasolle","year":"2019","journal-title":"Endocr Connect"},{"key":"B62","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-016-1728-4","article-title":"Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly","volume":"58","author":"Shen","year":"2016","journal-title":"Neuroradiology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-005-1756-2","article-title":"Poor Responses to a Test Dose of Subcutaneous Octreotide Predict the Need for Adjuvant Therapy to Achieve \u201cSafe\u201d Growth Hormone Levels","volume":"7","author":"Lindsay","year":"2004","journal-title":"Pituitary"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302004000200007","article-title":"A utiliza\u00e7\u00e3o da octreotida subcut\u00e2nea ou LAR como teste preditivo e no tratamento da acromegalia","volume":"48","author":"Halah","year":"2004","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02073","article-title":"The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly","volume":"154","author":"Pokrajac","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2005.02.007","article-title":"Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly","volume":"15","author":"Biermasz","year":"2005","journal-title":"Growth Horm IGF Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02191.x","article-title":"The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02278.x","article-title":"The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly","volume":"62","author":"Gilbert","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.04.007","article-title":"Unmasking a new prognostic marker and therapeutic target from the GDNF-RET\/PIT1\/p14ARF\/p53 pathway in acromegaly","volume":"43","author":"Chenlo","year":"2019","journal-title":"EBioMedicine"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e66927","DOI":"10.1371\/journal.pone.0066927","article-title":"Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery","volume":"8","author":"Lekva","year":"2013","journal-title":"PloS One"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1760","article-title":"Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly","volume":"97","author":"Lekva","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2564","article-title":"Identification and Characterization of Two Novel Truncated but Functional Isoforms of the Somatostatin Receptor Subtype 5 Differentially Present in Pituitary Tumors","volume":"94","author":"Dura\u00e1n-Prado","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): Development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01335-0","article-title":"Somatostatin receptor expression and patients\u2019 response to targeted medical treatment in pituitary tumors: evidences and controversies","volume":"43","author":"Gatto","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response","author":"Chiloiro","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00135","article-title":"In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.07.005","article-title":"Absence of somatostatin SST2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model","volume":"644","author":"Waser","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr Connect"},{"key":"B85","article-title":"The biochemical effect of somatostatin analogs on somatotroph-specific aryl hydrocarbon receptor interacting protein knock out mice","volume-title":"The Endocrine Society\"s 97th Annual Meeting","author":"Lee","year":""},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1210\/me.2012-1329","article-title":"Phosphorylation of Threonine 333 Regulates Trafficking of the Human sst5 Somatostatin Receptor","volume":"27","author":"Petrich","year":"2013","journal-title":"Mol Endocrinol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1210\/me.2009-0315","article-title":"Pasireotide and Octreotide Stimulate Distinct Patterns of sst2A Somatostatin Receptor Phosphorylation","volume":"24","author":"Po\u00f6ll","year":"2010","journal-title":"Mol Endocrinol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1630","article-title":"The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly","volume":"95","author":"Bernabeu","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0391","article-title":"Clinical and Biochemical Impact of the d3 Growth Hormone Receptor Genotype in Acromegaly","volume":"93","author":"Mercado","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.19.02972-9","article-title":"Acromegaly in the era of precision medicine","volume":"44","author":"Pic\u00f2","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.18.02937-1","article-title":"Precision medicine in the treatment of acromegaly","volume":"44","author":"Puig-Domingo","year":"2019","journal-title":"Minerva Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.648411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T08:35:43Z","timestamp":1615883743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.648411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":91,"alternative-id":["10.3389\/fendo.2021.648411"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.648411","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"article-number":"648411"}}